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ABSTRACT
Objective To evaluate the effectiveness of a monovalent
rotavirus vaccine against severe rotavirus disease and to
assess its impact on diarrhoea in children aged less than
2 years after national introduction in El Salvador, a low-
middle income country in Central America.
Design Matched case-control study.
Setting Seven hospitals in cities across El Salvador,
January 2007 to June 2009.
Participants323childrenagedlessthan2yearsadmitted
with laboratory confirmed rotavirus diarrhoea and 969
healthy controls matched for age and neighbourhood.
Main outcome measure Effectiveness of rotavirus
vaccination ((1–adjusted odds ratio of vaccination)×100)
against rotavirus diarrhoea requiring hospital admission.
Results Cases and controls were similar for breast
feeding, premature birth, maternal education, and
socioeconomic variables. G1P[8] strains were identified
in 92% of rotavirus cases. Effectiveness of two doses of
vaccination against diarrhoea requiring hospital
admission was 76% (95% confidence interval 64% to
84%). Protection was significantly lower (P=0.046)
among children aged 12 months or more (59%, 27% to
77%) compared with children aged 6-11 months (83%,
68%to91%).Onedoseofvaccinewas51%(26%to67%)
effective. At the sentinel hospitals, all admissions for
diarrhoea among children under 5 declined by 40% in
2008andby51%in2009fromtheprevaccineyear2006.
Conclusions A monovalent rotavirus vaccine was highly
effective against admissions for rotavirus diarrhoea in
children aged less than 2 years in El Salvador and
substantially reduced the number of such admissions in
this low-middle income setting. The impact on disease
epidemiology after vaccination, particularly among older
children, warrants future attention.
INTRODUCTION
Globally,rotavirusrelateddiarrhoeaisresponsiblefor
527000 deaths and 2.4 million admissions to hospital
each year among children under 5 years.
12 Two live
attenuated oral rotavirus vaccines, a pentavalent
bovine derived vaccine (RotaTeq; Merck Vaccines,
Whitehouse Station, NJ) and a monovalent human
rotavirus vaccine (Rotarix; GlaxoSmithKline Biologi-
cals, Rixensart, Belgium) with good efficacy against
severe rotavirus infection and a reassuring safety pro-
file could have a substantial impact on the global bur-
den of severe diarrhoea in childhood.
3-6 In 2006 the
World Health Organization strongly recommended
theinclusionofrotavirusvaccinesintonationalimmu-
nisation programmes in American and European
countries, and in April 2009 WHO extended this
recommendation to all regions of the world.
78
In making a global recommendation for rotavirus
vaccines and noting the variable performance of the
vaccines in different populations, WHO emphasised
theneedforfurtherefficacyandeffectivenessdata,par-
ticularly in developing countries.
8 For example, the
efficacy of monovalent vaccine against severe rota-
virus diarrhoea was 96% (95% confidence interval
83% to 99%) in Europe, 83% (73% to 90%) in Latin
America, 72% (40% to 88%) in South Africa, and 49%
(11% to 72%) in Malawi.
3-59 Similarly, the pentavalent
vaccine prevented 98% (88% to 100%) of severe rota-
virus infections in the United States and Finland, but
effectiveness was 46% (18% to 64%) in Nicaragua, the
only developing country setting for which data are
available on the performance of the pentavalent
vaccine.
610 Experience with previous candidate rota-
virus vaccines, as well as vaccines against polio, cho-
lera, and typhoid, indicates that the immunogenicity
and efficacy of live, oral vaccines can be impaired in
developing countries of low and low-middle
income.
11-15 Therefore, studies on effectiveness after
the introduction of vaccine and surveillance of rota-
virus before and after the introduction of vaccine are
vital to understand further the performance of rota-
virus vaccines and their potential impact on the virus
strainsintargetpopulationswhoaremostlikelytoben-
efit from vaccination.
1617
El Salvador is a low-middle income country in Cen-
tral America, with a gross national income of $2850
(£1974; €2294) per capita and an annual birth cohort
of around 158000.
18 In October 2006 the ministry of
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twodoses)toitsnationalchildhoodimmunisationpro-
gramme, providing the first opportunity to assess per-
formance of the vaccine during programmatic use in a
low-middle income country. The first dose is recom-
mended at 2 months of age (between 6 and 14 weeks)
and the second at 4 months of age (between 16 and
24 weeks); the maximum upper age limit is 24 weeks.
Before the introduction of the vaccine, rotavirus was
responsible for an estimated 35% of the admissions
fordiarrhoeainElSalvador,andalthoughdataonrota-
virus strains from El Salvador are sparse, the G1P[8]
strain predominated in 2001 and G2P[4] in 2006.
1920
We assessed the effectiveness of two doses of the
monovalent vaccine against rotavirus diarrhoea
requiring hospital admission in El Salvador and com-
paredthetotalnumberofadmissionsfordiarrhoeaand
for rotavirus at sentinel hospitals in El Salvador before
and after the introduction of the vaccine.
METHODS
From January 2007 to June 2009 we carried out a
nationally representative matched case-control study
to evaluate the effectiveness of the monovalent rota-
virusvaccineagainstadmissionforrotavirusdiarrhoea
in children under 5 using a standardised WHO
protocol.
17 El Salvador has 14 departments, five of
which have the highest population density and consti-
tute about 60% of El Salvador’s annual birth cohort.
From these regions the ministry selected seven hospi-
tals where an estimated 48% of El Salvador’s annual
admissionsfordiarrhoeaoccurredinchildrenunder5.
Participants
Cases
In January 2006 the ministry of health established a
hospital based surveillance system to identify children
with rotavirus diarrhoea who were admitted for dehy-
dration at one of the seven sentinel hospitals. Active
surveillance was carried out continuously in the emer-
gency department and inpatient wards in children
under 5 with acute diarrhoea, defined as three or
more loose stools in a 24 hour period and with onset
less than 14 days before the hospital visit. Healthcare
providers in the seven hospitals were encouraged to
notify the surveillance coordinator when treating a
child under 5 with diarrhoea. The admission log was
also reviewed daily to identify cases of diarrhoea. The
surveillance coordinator interviewedthe providerand
the parent to assess case eligibility and subsequently
collected bulk stool specimens within 48 hours of
admission.
Specimenswerestoredat2-8°Cbeforedailytransfer
to the national laboratory, where rotavirus testing was
done using a commercially available enzyme immu-
noassay (IDEIA; Oxoid, Ely, Cambridge). Specimens
were frozen at −70°C and shipped to the Centers for
DiseaseControlandPreventioninAtlanta,wherethey
were maintained at −70°C. Rotavirus positive
specimens were then genotyped using previously
described methods to determine the infecting
strain.
21-24
Controls
For each case we enrolled three controls from the
neighbourhood who were individually matched to
the case’s date of birth (within 30 days). We selected
controls through cumulative incidence sampling after
the rotavirus season in 2007 and incidence density
samplingonaweeklybasisin2008and2009.Controls
were enrolled when interviewers visited homes to the
left and right of the case’s home until three controls
were identified. Enrolment was restricted to one con-
trol per household. To avoid selection bias of positive
respondents, we prohibited re-enrolment of controls
once they were matched to a case. Written informed
consent to participate was obtained from parents or
guardians before enrolment.
Variables
During 2007, only information on vaccination status
was gathered from cases and controls because of logis-
ticaldelaysfromhiringandtrainingstudystaff.During
2008-9,inadditiontovaccinationhistory,weobtained
information on demographics, socioeconomic factors,
birth weight, premature birth (<36 weeks’ gestational
age), current body mass index, history of breast feed-
ing, and medical history; for cases, we also gathered
information on clinical characteristics, treatment, and
course of illness. We classified the gradient of severity
amongcasesadmittedforrotavirusdiarrhoeausingthe
previously described 20 point Vesikari scale.
2526 We
computed effectiveness of the monovalent vaccine
against rotavirus diarrhoea using severity scores of 11
or more and 15 or more.
Data sources
We interviewed the parents of cases and controls face
to face. Vaccination was confirmed if the parent
showedavaccinationcardwiththedateofvaccination,
type of vaccine used, and the child’s name. If parents
reported vaccination but did not possess a card, we
reviewed vaccine records at the clinic where the child
was reportedly vaccinated.
Sample size for vaccine effectiveness
We calculated precision based sample size estimates
foramatcheddesignunderthefollowingassumptions:
vaccine coverage 50% and vaccine effectiveness 70%,
with a confidence limit width of 30%.
27 We estimated
that about 150 cases of severe rotavirus diarrhoea
(admission or Vesikari score ≥11) and a control to
case ratio of 3 to 1 would be sufficient for our primary
analysis. Although we did not specifically power the
study for subgroup analyses, we anticipated enrolling
about 300 cases to allow us to carry out exploratory
analysis on partial dose effectiveness and potential
modification of effectiveness by age and to assess
RESEARCH
page 2 of 7 BMJ | ONLINE FIRST | bmj.comeffectiveness against the most severe diarrhoea (Vesi-
kari score ≥15).
Statistical analysis
Our primary analysis assessed effectiveness of two
doses of the monovalent vaccine against laboratory
confirmed rotavirus diarrhoea requiring hospital
admission. Consecutive cases admitted for laboratory
confirmed rotavirus diarrhoea and born after 1 June
2006 were included in the vaccine effectiveness analy-
sis, thus making them age eligible to receive the vac-
cine. Preplanned subgroup analyses were done to
assess effectiveness by case severity, protection from
one dose of vaccine, and duration of vaccine protec-
tion. We assessed partial series protection from one
dose of vaccine and we also carried out an “intention
to vaccinate” analysis to assess the effectiveness of one
or more doses. To assess duration of protection we
chose two specified groups for age at disease onset:
6-11 months and 12 months or more.
Weconsideredcasesandcontrolstobevaccinatedif
the most recent dose was administered 14 days before
the case’s hospital visit (reference date). We used con-
ditionallogistic regressiontoestimatethe oddsratio of
vaccination in cases comparedwith controls, assessing
for effect modification by hospital, socioeconomic sta-
tus, and age by including interaction terms in the
model. To identify variablesthat changed the estimate
by more than 10% we used models controlling for fac-
tors potentially associated with vaccination and rota-
virus disease—sex, history of breast feeding, daycare
attendance, birth weight, and variables of socioeco-
nomic status (maternal education, ownership of a
motorised vehicle, and electricity, telephone, or com-
puter in the home). These factors were selected on the
basis of recommendations from a WHO guideline
document.
17
Wealsocomparedthenumberofadmissionstohos-
pital for all cause diarrhoea and for rotavirus in 2008
and2009againsttheprevaccineyear2006,attheseven
surveillance hospitals that applied the same surveil-
lance methodology. We restricted this analysis to Jan-
uary to June, the months of peak rotavirus activity, or
“rotavirus season.”
Weestimatedtheadjustedoddsratiousingtheexpo-
nentialofthe coefficientforthe vaccinationvariablein
the model. The 95% confidence interval for the
adjusted odds ratio was computed using the standard
error of the coefficient
28 and subsequently we calcu-
lated vaccine effectiveness for each group of controls
as (1–adjusted odds ratio of vaccination)×100.
29 We
used the Wilcoxon rank sum test, trends test, or χ
2
test to assess the differences in characteristics of chil-
dren with rotavirus gastroenteritis and their matched
controls. Statistical significance was designated as a
two tailed P value <0.05. All analyses were done
using SAS statistical software (version 9.2).
RESULTS
For the vaccine effectiveness study, 323 consecutive
cases of rotavirus diarrhoea were age eligible for
immunisation against rotavirus. Of the 81 children
who were age eligible for vaccination during the 2007
rotavirus season (aged ≤6 months), 72 (89%) partici-
pated; the parents of the remaining children could
not be located. Of the children who were age eligible
for vaccination (n=256), 251 (98%) participated: 113
during 2008 and 138 during 2009. All cases were
admittedfordehydratingdiarrhoea.Threeneighbour-
hoodcontrolsmatchedbydateofbirthwereidentified
for each case. Of the eligible controls who were at
home during the community visit (n=979), 969 (99%)
Table 1 |Characteristics of rotavirus positive cases and neighbourhood controls in El
Salvador, 2008 and 2009*. Values are numbers (percentages) unless stated otherwise
Variables
Rotavirus positive
cases† (n=251)
Neighbourhood
controls‡ (n=753) P value
Median (range) age
(months)
10 (1-24) 10 (1-25) 0.96§
Male 161 (64) 378 (50) <0.001
History of breast feeding 228 (91) 701 (93) 0.25
Daycare attendance 9 (4) 17 (2) 0.94
Premature birth 35 (14) 95 (13) 0.58
Maternal education:
None 16 (6) 51 (7)
0.17¶
Primary school 162 (65) 528 (70)
Secondary school 52 (21) 136 (18)
Tertiary school 13 (5) 29 (4)
Median (range) No of
children in household
1 (0-10) 1 (0-21) 0.006§
Median (range) No of
people in household
2 (0-10) 2 (0-9) 0.04§
Socioeconomic variables:
Electricity in home 235 (94) 717 (95) 0.19
Owned motorised
vehicle
24 (10) 71 (9) 0.96
Telephone in home 178 (71) 529 (70) 0.82
Computer in home 13 (5) 40 (5) 0.94
*Variables not collected during 2007 surveillance year.
†Children admitted to hospital with acute diarrhoea who tested positive for rotavirus on enzyme immunoassay
of stool.
‡Neighbourhood controls matched by age (within 30 days).
§Wilcoxon rank sum test.
¶Cochran-Armitage trend test.
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controls was 10 months (range 1-25 months). Cases
were more likely than controls to be male (64% v
50%;P<0.001)butweresimilarforbreastfeeding,pre-
mature birth, maternal education, and socioeconomic
variables (table 1).
Cases were admitted to hospital for a median dura-
tion of two days; 98% (247/251) received intravenous
hydration and none died. Among the 239 cases with
information on severity, 16 (7%) had a Vesikari score
of10or less,223 (93%)11ormore,and 54(22%)15or
more. Sufficient volume of stool was available for
strain characterisation from 70% (225/323) of the
cases. Among these samples, 92% (208/225) of the
strains were G1P[8].
In cases (n=323) and controls (n=969), vaccine his-
tory was verified by vaccination card (93% (n=301)
cases, 97% (n=944) controls) or clinic record (7%
cases (n=22), 3% (n=25) controls). Adherence to the
age recommendations for monovalent vaccine was
good, with only 8% (14/175) of the vaccinated cases
and 7% (48/687) of the vaccinated controls receiving
their second dose of vaccine beyond 6 months of age.
Amongthecases,31%(n=99)wereunvaccinated,22%
(n=72) received one dose of the vaccine, and 47%
(n=1522) received two doses (table 2). In contrast,
16% (n=153) of community controls were unvacci-
nated, 21% (n=199) received one dose of vaccine, and
64%(n=617)receivedtwodoses(table 2).Vaccination
rates did not differ by sex.
No confounding factors were identified in the study
and thus the final model included vaccination as the
independent variable only. Effectiveness against rota-
virus diarrhoea requiring hospital admission after two
doses of vaccine was 76% (95% confidence interval
64% to 84%) and after one dose was 51% (26% to
67%; table 2). Effectiveness estimates were similar
between2007(77%)and2008-9(75%).Intheintention
to vaccinate analysis, protection from one or more
doses of vaccine was 67% (95% confidence interval
54%to77%).Noheterogeneityinvaccineeffectiveness
was identified between hospitals (P=0.12) or between
children of low and high socioeconomic status
(P=0.89).
Subgroup analysis assessedeffectivenessby severity
and age. Two doses of vaccine were 83% (95% confi-
dence interval 52% to 94%) effective against rotavirus
diarrhoea with a severity score of 15 or more and 73%
(56%to84%)effectiveagainstrotavirusdiarrhoeawith
a severity score of 11 or more (table 3). We assessed
duration of protection after vaccination by comparing
rates of vaccination among cases and controls in chil-
dren aged 6-11 months compared with those aged
12 months or older. Protection against admission for
rotavirus related diarrhoea was 83% (95% confidence
interval68%to91%)inchildrenaged6-11monthsand
59%(27%to77%)inchildrenaged12 monthsorolder
(table 4; P=0.046).
Vaccine impact
Using the same surveillance methodology, between
January 2006 and June 2009, 2702 of 8151 (33.1%)
children aged less than 5 years requiring overnight
admission for episodes of diarrhoea at the seven sur-
veillance hospitals were positive for rotavirus in their
stool. Most (about 98%) of the cases were identified
during January to June. During these months the pre-
valence of rotavirus was 62% in 2006, 49% in 2007,
16% in 2008, and 40% in 2009 (figure). Admissions
for diarrhoea among children under 5 decreased
from 1771 in 2006, before the introduction of vaccine,
to 1066 in 2008 (40% reduction) and to 863 in 2009
(51% reduction). Thenumberoflaboratory confirmed
rotavirus related admissions in children under 5
decreased from 1092 in 2006 to 171 in 2008 (84%
reduction) and to 342 in 2009 (69% reduction) at the
same surveillance sites (figure).
DISCUSSION
InApril2009,WHOstronglyrecommendedtheintro-
duction of rotavirus vaccines into national immunisa-
tion programmes worldwide, but noted a need for
ongoing monitoring of vaccine performance on the
basis of variable efficacy of the vaccines in different
populations.
8 Under routine use in a low-middle
income country, we have shown that the monovalent
Table 2 |Effectiveness of rotavirus vaccine against admissions for rotavirus related diarrhoea
in El Salvador, 2007-9
Vaccine dose
No (%) of rotavirus
positive cases
(n=323)
Neighbourhood controls (n=969)
No (%) Odds ratio (95% CI)
% vaccine effectiveness
(95% CI)*
0 dose (referent) 99 (31) 153 (16) ——
1d o s e † 72 (22) 199 (21) 0.49 (0.33 to 0.74) 51 (26 to 67)
2d o s e s ‡ 152 (47) 617 (64) 0.24 (0.16 to 0.36) 76 (64 to 84)
*Conditional logistic regression was used to calculate vaccine effectiveness. Models that included sex, history
of breast feeding, daycare attendance, birth weight, and variables of socioeconomic status did not alter odds
ratio and therefore final model included only vaccination as independent variable; adjustment factors were
considered important if P<0.05 or estimates were changed by 10%.
†Protection conferred after 14 or more days of vaccination (includes children admitted before additional doses).
‡Protection conferred after 14 or more days of vaccination.
Table 3 |Subgroup analysis to assess effectiveness of rotavirus vaccine against rotavirus
diarrhoea of severity scores 11 or more and 15 or more, El Salvador 2008 and 2009*
Severity score and vaccine
dose
No (%) of rotavirus
positive cases
Neighbourhood controls
No (%)
% vaccine effectiveness
(95% CI)†
Vesikari score ≥11: n=223 n=669
0d o s e( r e f e r e n t ) 5 3( 2 4 ) 8 8( 1 3 ) —
1d o s e ‡ 49 (22) 113 (17) 36 (−9t o6 3 )
2d o s e s § 121 (54) 468 (70) 73 (56 to 84)
Vesikari score ≥15: n=54 n=162
0d o s e( r e f e r e n t ) 1 5( 2 8 ) 2 2( 1 4 ) —
1d o s e ‡ 14 (26) 26 (16) 45 (−60 to 81)
2d o s e s § 25 (46) 114 (70) 83 (52 to 94)
*Data on clinical variables for severity not available for 2007 (n=72).
†Final model included only vaccination as independent variable (see footnote to table 2); adjustment factors
were considered important if P<0.05 or estimates were changed by 10%.
‡Protection after one dose after 14 or more days of vaccination (includes children admitted before additional
rotavirus vaccine doses).
§Protection after two doses after 14 or more days of vaccination.
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admissions for rotavirus among children under
2years,whichwasonlyslightlylowerthantheefficacy
of 85% observed in a clinical trial of the monovalent
vaccine in other middle income Latin American
countries.
34Recentstudiesindicatethatthepopulation
level benefits of vaccination are likely to be greater in
thepoorestsettingswiththehighestincidence,andper-
haps even greater than expected on the basis of direct
effects of rotavirus vaccination.
930Moreover, the find-
ingthatonedoseofmonovalentvaccineconfersabout
50% protection indicates that vaccination could also
have an impact between 2 and 6 months of age when
a substantial proportion of admissions to hospital and
deaths from rotavirus related disease occur. More
encouragingly, routine use of monovalent vaccine
has substantially reduced the health burden of admis-
sions for rotavirus and all cause diarrhoea during the
winter months in this setting. The 40% to 51% reduc-
tioninallcausediarrhoeaamongchildrenunder5was
substantially greater than expected because few chil-
dren aged more than 2 years were vaccinated during
the study period, a potential indicator of indirect ben-
efits to unvaccinated membersof the community from
interruptionoftransmission.Ourfindingofhigheffec-
tiveness of the monovalent vaccine and noticeable
impact over a three year study span in this challenging
population reinforces the WHO recommendation for
childhood rotavirus vaccination and provides further
support for vaccination as an important measure in
reducing global rotavirus related morbidity and mor-
tality.
Comparison with other studies
The protection of 76% conferred by the monovalent
vaccine in El Salvador seems to be greater than the
protection of about 50% conferred by the vaccine
against rotavirus diarrhoea requiring admission in a
similar study in the neighbouring country of
Nicaragua,
10wheretheintroductionofthepentavalent
vaccineoccurredsimultaneouslywiththeintroduction
ofthemonovalentvaccineinElSalvador.Thesediffer-
ences may in part be attributable to differences in the
severity of rotavirus disease among people evaluated
in the two countries. Rotavirus vaccines have lower
efficacy against milder disease, and 33% of the cases
with rotavirus admitted in Nicaragua compared with
only 7% in El Salvador had a severity score of 10 or
less.However,theeffectivenessofthemonovalentvac-
cinein El Salvadorseemedto be21% greaterthan that
ofthepentavalentvaccineinNicaragua,evenwhenthe
comparisonwasrestrictedtocaseswiththesamesever-
ity. Differences in vaccine formulation and circulating
strains during the study period might explain some of
the variation, although both vaccines have provided
good heterotypic and homotypic protection against
common strains in high and middle income
settings.
356 Differences in host and environment
between the two populations could also be a factor, as
ElSalvadorisalow-middleincomecountrywithgross
national income of $2850 per capita whereas Nicara-
gua is a low income country with a gross national
incomeof$980percapita.Themostimpoverishedset-
tingsmayposegreaterchallenges(forexample,higher
inoculumsof infection, greaterrates of coentericinfec-
tions, gut enteropathy, micronutrient malnutrition, or
high levels of circulating maternal antibodies) to the
performance of oral rotavirus vaccines.
1131 Indeed,
the lowest observed efficacy of the monovalent vac-
cine, 50%, has been in Malawi, one of the poorest set-
tings in which the vaccine has been tested to date.
Resultsofongoingclinicaltrialsofthepentavalentvac-
cine in poor countries of Africa and Asia are expected
inthenextfewmonthsandwillprovidekeyadditional
datatounderstandbettertheperformanceoforalrota-
virus vaccines in challenging developing country set-
tings.
Effectiveness of the monovalent vaccine seemed to
be lower among children aged 12-24 months (59%)
comparedwiththoseaged6-11months(83%),suggest-
ingthe possibilityofwaningimmunity.Thisdeclinein
protection in children aged more than 1 year was sur-
prising, because overall protection against homotypic
and many heterotypic strains was high and sustained
(79-96%)throughtwoyearsinthe EuropeanandLatin
America monovalent vaccine trials.
35 However, effi-
cacy trials of previous rotavirus vaccines and studies
of protection after natural rotavirus disease have also
observed a decline in immunity to vaccine or wild
virus, especially in poor settings.
32-36 In Nicaragua,
the pentavalent vaccine also showed a lower (but not
statistically significant) effectiveness among children
aged12–19months.
10Similarly,inasmallcase-control
study in an impoverished population in Brazil, the
monovalent vaccine conferred good protection (85%,
95% confidence interval 54% to 90%) during the first
year against diarrhoea from fully heterotypic G2P[4]
Table 4 |Effectiveness of rotavirus vaccine stratified by age at time of admission to hospital
Subgroups
No/total No (%) receiving two doses of vaccine
(v 0 doses)
% vaccine effectiveness*
(95% CI)
Rotavirus positive
cases
Neighbourhood
controls
Admitted rotavirus
cases:
All ages 152/251 (61) 617/770 (80) 76 (64 to 84)
Age 6-11 months 49/63 (78) 205/222 (92) 83 (68 to 91)
Age 12-24 months 79/108 (73) 284/335 (85) 59 (27 to 77)
Vesikari score ≥11†:
All ages 121/174 (70) 468/556 (84) 73 (56 to 84)
Age 6-11 months 45/57 (79) 188/203 (93) 79 (47 to 91)
Age 12-24 months 74/99 (75) 263/309 (85) 58 (21 to 78)
Vesikari score ≥15†:
All ages 25/40 (63) 114/136 (84) 83 (52 to 94)
Age 6-11 months 11/16 (69) 52/56 (93) 92 (46 to 99)
Age 12-24 months 14/19 (74) 58/68 (85) 58 (−67 to 89)
Variables not collected for diarrhoea severity during 2007 surveillance year.
*Final model included only vaccination as independent variable (see footnote to table 2); adjustment factors
were considered important if P<0.05 or estimates were changed by 10%.
†Protection conferred against rotavirus diarrhoea by two doses 14 or more days after vaccination.
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among children older than 12 months.
37 It is possible
that waning of vaccine induced immunity is greater in
developing countries where the short lived intestinal
immune response to vaccination may predominate,
and a systemic response may be less robust.
31 Further-
more, immune responses against homotypic strains
may be longer lasting than against heterotypic
strains.
33 Potential waning of immunity during the
first 2 to 3 years of age could contribute to important
changesindiseaseepidemiology,suchasanincreasein
severediseaseamongolderagegroupscomparedwith
baseline, thus warranting close monitoring through
surveillance and epidemiological studies. However,
given the wide confidence limits, caution is warranted
in interpreting findings of lower effectiveness among
older children. Additional evaluations, including
results from the second year of follow-up of ongoing
clinical trials of the monovalent vaccine in developing
countriesinAfrica,willhelpassessthedurationofpro-
tection after vaccination.
Strengths and limitations of the study
The observational nature of case-control studies war-
rants discussion. We cannot be certain that controls in
our study ideally represent the source population to
which the cases belong. Matching the controls by age
andneighbourhoodislikelytolessenconfoundingbias
from these factors. We were further reassured by simi-
larities in measures of socioeconomic variables
between cases and controls in our study. Although
cases were more likely to be male, sex was not a con-
founder because vaccination rates were similar
between the sexes. We were also able to confirm vac-
cination history by review of the vaccination card or
registry on all cases and controls thus minimising
potential misclassification of vaccination status. Mis-
classification of children who had been vaccinated to
non-vaccinated is possible, in the event of a failure to
documentvaccinationattimeofreceiptandcouldthe-
oretically lower our effectiveness estimates. However,
any such misclassification would likely be equal in
both cases and controls and thus unlikely to affect our
effectivenessestimatessubstantially.Logisticalreasons
prohibited us from blinding interviewers to case and
control status, which might have introduced some
bias. In addition, although cases and controls were
matched on neighbourhood, in 2007 we collected
data on rotavirus disease and vaccination status only.
However, similar vaccine effectiveness estimates were
observed when we restricted analysis to 2008-9 alone.
It is also reassuring that during 2008 and 2009, cases
and controls were similar for socioeconomic condi-
tions, body mass index, birth weight, and breast feed-
ing. All other surveillance methods were consistent
during the four rotavirus seasons when rotavirus sur-
veillancewasdone,andwedonotsuspectanysubstan-
tial differences in healthcare seeking patterns between
these years. Lastly, although an estimated 50% of the
admissions for rotavirus in El Salvador occur at the
study hospitals, these cases may not represent the full
spectrum of severe cases in the population. Although
clustering by hospital is possible, including hospital as
a random effect in the conditional regression model
did not substantially alter the presented findings.
Withregardtothedeclineinallcausediarrhoeaand
rotavirus related admissions at the sentinel hospitals,
secular variations in disease and changing reporting
practices might have led to an observed reduction in
diseaseafterthe introductionofvaccine.However,the
contention that vaccine may have contributed to the
reduction is supported by three findings: the high vac-
cine effectiveness in the case-control study, the sub-
stantial reduction in laboratory confirmed admissions
to hospital for rotavirus at seven hospitals with active
surveillance for diarrhoea before and after the vaccine
was introduced, and the reduction in episodes of all
cause diarrhoea observed during the winter season,
when 98% of the laboratory confirmed rotavirus dis-
ease among children aged less than 5 years occurs in
ElSalvador.Wewereintriguedbytherelativeincrease
in rotavirus prevalence among children under 5
between 2008 (16%) and 2009 (40%). Although the
shortdurationofsurveillancelimitsourinterpretation,
the increase in rotavirus prevalence could be from
secular variation in rotavirus and other causes of diar-
rhoea, or might reflect the decreased effectiveness
among older children or an accumulation in 2009 of
older susceptible children who were not exposed at
an earlier age because of the noticeably diminished
2008 season. Despite an increase in rotavirus preva-
lence, a noticeable decline in the absolute number of
admissionsforrotavirusrelateddiarrhoeaandallcause
diarrhoeain2009from2006stillindicatesasubstantial
impact from the vaccine. This finding highlights the
need for good baseline surveillance for evaluating
and interpreting post licensure changes in the epide-
miology of rotavirus.
Conclusions and policy implications
In summary, the monovalent vaccine provided good
protection against admissions for rotavirus diarrhoea
in El Salvador. Protective immunity was obtained
WHAT IS ALREADY KNOWN ON THIS TOPIC
Themonovalentrotavirusvaccinehasshownhighefficacyandgoodsafetyunderclinicaltrial
settings in Europe and middle-high income countries of Latin America
A lower performance of live attenuated oral rotavirus vaccines has been observed in
developing countries with the highest burden of severe rotavirus disease
WHAT THIS STUDY ADDS
A monovalent rotavirus vaccine was highly effective against admissions for rotavirus
diarrhoea in children aged less than 2 years in El Salvador, providing 76% protection
The substantial decline in diarrhoea episodes and severe rotavirus disease in El Salvador
indicates that the population level benefits of vaccination in this low-middle income setting
may potentially be greater than expected on the basis of direct vaccine protection
The lower effectiveness among older children highlights the importance of monitoring
disease epidemiology after vaccination through robust surveillance systems
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page 6 of 7 BMJ | ONLINE FIRST | bmj.comafter one dose, which is administered at an age before
an appreciable proportion of rotavirus cases occur.
Carrying out rotavirus surveillance before and after
vaccination and monitoring performance of rotavirus
vaccination in different populations will allow a more
complete assessment of the level and duration of pro-
tectioninvariedconditionsandthepotentialinfluence
of vaccination on disease epidemiology and virus
strains.
We thank the sentinel hospital rotavirus surveillance team in El Salvador
for enrolling participants.
Contributors: O d P ,L C ,H R ,A d B ,N V ,a n dD Pd e s i g n e dt h es t u d ya n d
collected the data. LHdO and UP designed the study, reviewed the data,
and revised the manuscript. TK, MB, JG, JT, and DE analysed the data. MP
oversaw the study and analysed the data. All authors reviewed the data,
revised the manuscript, and have seen and approved the final version.
Thefindingsandconclusionsinthisreportarethoseoftheauthorsanddo
not necessarily represent the views of the Centers for Disease Control
and Prevention.
Funding: This work was carried out under a collaborative arrangement
with Program for Appropriate Technology in Health and was funded in
part by the GAVI Alliance. The funders had no role in the study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing interests: All authors have completed the unified competing
interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare (1) no financial support for
the submitted work from anyone other than their employer; (2) no
financial relationships with commercial entities that might have an
interest in the submitted work; (3) no spouses, partners, or children with
relationships with commercial entities that might have an interest in the
submittedwork;and(4)nonon-financialintereststhatmayberelevantto
the submitted work.
Ethical approval: This study was approved by the PanAmerican Health
Organization Program for Appropriate Technology in Health, and the El
Salvador Ministry of Health.
Data sharing: No additional data available.
1 Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe
childhood diarrhea. Emerg Infect Dis 2006;12:304-6.
2 ParasharUD,BurtonA,LanataC,Boschi-PintoC,ShibuyaK,SteeleD,
et al. Global mortality associated with rotavirus disease among
children in 2004. JI n f e c tD i s2009;200(suppl 1):9-15S.
3 Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H,
EspinozaF,etal.Efficacyandsafetyofanoralliveattenuatedhuman
rotavirus vaccine against rotavirus gastroenteritis during the first
2 years of life inLatin American infants: a randomised, double-blind,
placebo-controlled phase III study. Lancet 2008;371:1181-9.
4 Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T,
Clemens SC, et al. Safety and efficacy of an attenuated vaccine
against severe rotavirus gastroenteritis. NE n g lJM e d
2006;354:11-22.
5 Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R,
et al. Efficacy of human rotavirus vaccine against rotavirus
gastroenteritis during the first 2 years of life in European infants:
randomised, double-blind controlled study. Lancet
2007;370:1757-63.
6 Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M,
RodriguezZ,etal.Safetyandefficacyofapentavalenthuman-bovine
(WC3) reassortant rotavirus vaccine. NE n g lJM e d2006;354:23-33.
7 World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec
2007;82:285-95.
8 Meeting of the immunization Strategic Advisory Group of Experts,
April2009—conclusionsand recommendations.Wkly Epidemiol Rec
2009;84:220-36.
9 M a d h iS A ,C u n l i f f eN A ,S t e e l eD ,W i t t eD ,K i r s t e nM ,L o u wC ,e ta l .
Effect of human rotavirus vaccine on severe diarrhea in African
infants. NE n g lJM e d 2010;362:289-98.
10 Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al.
Association between pentavalent rotavirus vaccine and severe
rotavirus diarrhea among children in Nicaragua. JAMA
2009;301:2243-51.
11 Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD,
Glass RI. Update on rotavirus vaccines. Pediatr Infect Dis J
2005;24:947-52.
12 Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK,
Widdowson MA, et al. Rotavirus vaccines: current prospects and
future challenges. Lancet 2006;368:323-32.
13 John TJ. A developing country perspective on vaccine-associated
paralytic poliomyelitis. Bull World Health Organ 2004;82:53-7.
14 Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P,
et al. Effect of small bowel bacterial overgrowth on the
immunogenicity of single-dose live oral cholera vaccine CVD 103-
HgR. JI n f e c tD i s1999;180:1709-12.
15 Levine MM. Enteric infections and the vaccines to counter them:
future directions. Vaccine 2006;24:3865-73.
16 Sanchez-Padilla E, Grais RF, Guerin PJ, Steele AD, Burny ME,
Luquero FJ. Burden of disease and circulating serotypes of rotavirus
infection in sub-Saharan Africa: systematic review and meta-
analysis. Lancet Infect Dis 2009;9:567-76.
17 WHO.Genericprotocolformonitoringimpactofrotavirusvaccination
on gastroenteritis disease burden and viral strains. 2008. http://
whqlibdoc.who.int/hq/2008/WHO_IVB_08.16_eng.pdf.
18 UN Data. A world of information. 2010. http://data.un.org/.
1 9 G u a r d a d oJ A ,C l a r aW A ,T u r c i o sR M ,F u e n t e sR A ,V a l e n c i aD ,
Sandoval R, et al. Rotavirus in El Salvador: an outbreak, surveillance
and estimates of disease burden, 2000-2002. Pediatr Infect Dis J
2004;23(suppl 10):156-60S.
20 Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD.
Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis
2008;14:863-5.
21 Das BK, Gentsch JR, Cicirello HG, Woods PA, Gupta A,
Ramachandran M, et al. Characterization of rotavirus strains from
newborns in New Delhi, India. J Clin Microbiol 1994;32:1820-2.
22 Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, Flores J, et al.
Identification of group A rotavirus gene 4 types by polymerase chain
reaction. J Clin Microbiol 1992;30:1365-73.
23 Gouvea V,GlassRI,WoodsP,TaniguchiK,ClarkHF,ForresterB,etal.
Polymerase chain reaction amplification and typing of rotavirus
nucleic acid from stool specimens. J Clin Microbiol 1990;28:276-82.
24 Griffin DD, Nakagomi T, Hoshino Y, Nakagomi O, Kirkwood CD,
Parashar UD, et al. Characterization of nontypeable rotavirus strains
from the United States: identification of a new rotavirus reassortant
(P2A[6],G12) and rare P3[9] strains related to bovine rotaviruses.
Virology 2002;294:256-69.
25 Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM,
Gonzalez R, et al. Efficacy of the rhesus rotavirus-based quadrivalent
vaccine in infants and young children in Venezuela. NE n g lJM e d
1997;337:1181-7.
26 Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of
numerical scores for clinical severity of diarrhoeal episodes. Scand J
Infect Dis 1990;22:259-67.
27 Satten GA, Kupper LL. Sample size determination for pair-matched
case-controlstudieswherethegoalisintervalestimationoftheodds
ratio. J Clin Epidemiol 1990;43:55-9.
28 HosmerDW,LemeshowS.Appliedlogisticregression.2nded.Wiley,
2000.
29 Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ,
et al. Field evaluation of vaccine efficacy. Bull World Health Organ
1985;63:1055-68.
30 Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL,
et al. Decline and change in seasonality of US rotavirus activity after
the introduction of rotavirus vaccine. Pediatrics 2009;124:465-71.
3 1 P a t e lM ,S h a n eA L ,P a r a s h a rU D ,J i a n gB ,G e n t s c hJ R ,G l a s sR I .O r a l
rotavirus vaccines: how well will they work where they are needed
most? JI n f e c tD i s2009;200(suppl 1):39-48S.
32 Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation
of rhesus rotavirus monovalent and tetravalent reassortant vaccines
in US children. US Rotavirus Vaccine Efficacy Group. JAMA
1995;273:1191-6.
3 3 C h i b aS ,Y o k o y a m aT ,N a k a t aS ,M o r i t aY ,U r a s a w aT ,T a n i g u c h iK ,
et al. Protective effect of naturally acquired homotypic and
heterotypic rotavirus antibodies. Lancet 1986;2:417-21.
34 Linhares AC, Gabbay YB, Mascarenhas JD, de Freitas RB, Oliveira CS,
Bellesi N, et al. Immunogenicity, safety and efficacy of tetravalent
rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull
World Health Organ 1996;74:491-500.
35 Moulton LH, Staat MA, Santosham M, Ward RL. The protective
effectiveness of natural rotavirus infection in an American Indian
population. JI n f e c tD i s1998;178:1562-6.
3 6 S a n t o s h a mM ,M o u l t o nL H ,R e i dR ,C r o l lJ ,W e a t h e r h o l tR ,W a r dR ,
et al. Efficacy and safety of high-dose rhesus-human reassortant
rotavirus vaccine in Native American populations. JP e d i a t r
1997;131:632-8.
37 Correia JB, Patel MM, Nakagomi O, Montenegro FM, Germano EM,
Correia NB, et al. Effectiveness of monovalent rotavirus vaccine
(Rotarix) against severe diarrhea caused by serotypically unrelated
G2P[4] strains in Brazil. JI n f e c tD i s2010;201:363-9.
Accepted: 16 March 2010
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 7